Rasagiline
Rasagiline is a medication used to treat Parkinson’s disease. It is sold under brand names like Azilect and is taken by mouth, usually as a once-daily tablet. It can be used alone in early Parkinson’s or together with other Parkinson’s medicines in more advanced cases.
How it works: Rasagiline is a selective, irreversible inhibitor of the enzyme MAO-B. By blocking MAO-B, it helps keep dopamine levels higher in the brain, which can improve motor symptoms. Unlike some related drugs, rasagiline does not produce amphetamine-like metabolites.
What has been studied: Researchers have looked to see if rasagiline can slow the progression of Parkinson’s disease (not just treat symptoms). In major trials, the claim that it slows disease progression was not clearly proven, and U.S. regulators did not confirm disease-modifying effects.
Who should take it and how it’s used: The usual dose is 1 mg once daily. People with mild liver problems may need a lower dose (0.5 mg). Rasagiline should be avoided or used with caution in moderate to severe liver impairment. It can be taken with or without food.
Side effects and safety: Common side effects include headache, nausea, upset stomach, joint pain, flu-like symptoms, insomnia, and dizziness. A notable risk is drops in blood pressure when standing up (orthostatic hypotension), especially early in treatment. Rasagiline can interact with certain other drugs, including antidepressants and other drugs that affect serotonin, which can cause a dangerous reaction called serotonin syndrome. It is important to avoid combining rasagiline with other MAO inhibitors and certain stimulants, and to discuss all medicines with a healthcare provider. Rare but serious effects can include confusion, hallucinations, impulsive or compulsive behaviors, and a potential risk of melanoma noted on the labeling. Stopping rasagiline suddenly can also cause withdrawal-like symptoms in some people.
Other notes: Rasagiline is the R-enantiomer of AGN-1135 and is the main active MAO-B blocker in the drug. It does not convert into amphetamine-like substances, which distinguishes it from some older drugs. The medication may offer some non-motor benefits, such as mood improvement or reduced fatigue, but evidence varies and it is not approved as a treatment for depression.
History and availability: Rasagiline was approved in the European Union in 2005 and in the United States in 2006. Generic versions are available.
This page was last edited on 2 February 2026, at 23:09 (CET).